Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 30,114 | 13,993 | 192,645 | -175,218 | -609,693 |
| Depreciation Amortization | 18,139 | 12,997 | 8,531 | -469 | 15,351 |
| Accounts receivable | -56,967 | -9,841 | -2,365 | -2,500 | N/A |
| Accounts payable and accrued liabilities | 6,286 | 21,662 | -1,717 | 3,069 | -5,536 |
| Other Working Capital | -18,235 | 20,125 | 38,085 | -7,440 | 25,091 |
| Other Operating Activity | 200,215 | 100,125 | 78,602 | 36,286 | 111,936 |
| Operating Cash Flow | $179,552 | $159,061 | $313,781 | $-146,272 | $-462,851 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -796,258 | -774,616 | 347,402 | 84,426 | -720,947 |
| PPE Investments | -22,666 | -15,177 | -12,813 | -7,516 | -141,469 |
| Purchase Of Investment | N/A | N/A | -677,892 | N/A | N/A |
| Sale Of Investment | 689,630 | 587,880 | N/A | N/A | 442,344 |
| Investing Cash Flow | $-129,294 | $-201,913 | $-343,303 | $76,910 | $-420,072 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 10,260 | N/A | N/A | N/A | N/A |
| Debt Issued | N/A | 7,098 | N/A | N/A | 392,000 |
| Debt Repayment | -201,625 | -201,625 | N/A | N/A | N/A |
| Common Stock Issued | 270,371 | 269,864 | 269,641 | 25,634 | 431,654 |
| Other Financing Activity | -5,000 | -5,000 | -156,625 | -5,000 | 46,866 |
| Financing Cash Flow | $74,006 | $70,337 | $113,016 | $20,634 | $870,520 |
| Exchange Rate Effect | -401 | -377 | -470 | -68 | 4,197 |
| Beginning Cash Position | 102,685 | 102,685 | 102,685 | 102,685 | 110,891 |
| End Cash Position | 226,548 | 129,793 | 185,709 | 53,889 | 102,685 |
| Net Cash Flow | $123,863 | $27,108 | $83,024 | $-48,796 | $-8,206 |
| Free Cash Flow | |||||
| Operating Cash Flow | 179,552 | 159,061 | 313,781 | -146,272 | -462,851 |
| Capital Expenditure | -22,666 | -15,177 | -12,813 | -7,516 | -141,469 |
| Free Cash Flow | 156,886 | 143,884 | 300,968 | -153,788 | -604,320 |